Concord Biotech Ltd (CONCORDBIO) is currently trading at 1,474.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Concord Biotech Limited is an R&D-driven biopharmaceutical company that develops and manufactures fermentation-based active pharmaceutical ingredients (APIs), finished formulations and CDMO services, serving 70+ countries including regulated markets and maintaining over 140 DMFs and significant fermentation capacity across multiple Gujarat facilities. Q3 FY26 performance showed revenue improvement with consolidated quarterly revenue of INR 278 crore (up 14% YoY) driven by a 24% jump in API sales, while 9MFY26 revenue remained lower at INR 729 crore due to timing-related headwinds and geopolitical/tariff disruptions which management describes as temporary. Management received WHO‑GMP certification for the new injectable facility and quantified a peak revenue potential near INR 600 crore; they also set up Stellon Biotech in the US to commercialize Concord’s products directly, both actions materially expanding commercial channels and future revenue levers. Normalized EBITDA margins remain strong at around 40% when excluding one‑off commercialization and subsidiary setup costs, but reported 9MF EBITDA margin declined to ~34% due to injectable commercialization and Stellon setup expenses; company maintains zero net debt and a cash/investment base to pursue organic and inorganic opportunities.

Over the past 52 weeks, Concord Biotech Ltd has traded between a low of ₹987.05 and a high of ₹1,702.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Concord Biotech Ltd has a market capitalization of approximately 15,762.00. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Concord Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 57.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 15,762.00 Cr, Concord Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Concord Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Concord Biotech Ltd is 57.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The stock rose after Concord Biotech announced USFDA final approval for its ANDA for Tofacitinib Tablets in 5 mg and 10 mg strengths.

The stock gained after Concord Biotech announced USFDA approval for its ANDA for Tofacitinib tablets in 5 mg and 10 mg strengths.

The shares rose after Concord Biotech disclosed USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.

Concord Biotech received USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.